Dual-target chimeric antigen receptors simultaneously targeting lmp1 and gp350 and their applications

A chimeric antigen receptor, dual-target technology, applied in the direction of targeting specific cell fusion, peptides containing localization/targeting motifs, applications, etc., can solve problems such as off-target effects, and achieve low levels of secreted cytokines , The effect of reducing inflammatory cytokine storm and improving the conversion rate

Active Publication Date: 2022-02-22
THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chimeric antigen receptor (CAR) is the core component of CAR-T, which endows T cells with the ability to recognize tumor antigens in an HLA-independent manner. Although CAR-T cell therapy has achieved rapid development, CAR-T treatment of lymphoma also faces challenges. A range of challenges such as off-target effects and cytokine storms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual-target chimeric antigen receptors simultaneously targeting lmp1 and gp350 and their applications
  • Dual-target chimeric antigen receptors simultaneously targeting lmp1 and gp350 and their applications
  • Dual-target chimeric antigen receptors simultaneously targeting lmp1 and gp350 and their applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Dual-target CART plasmid construction

[0025] Plasmid construction

[0026] The gene sequence fragments were sequentially synthesized and connected: light chain of anti-GP350 single-chain antibody, heavy chain of anti-GP350 single-chain antibody, light chain of anti-LMP1 single-chain antibody, heavy chain of anti-LMP1 single-chain antibody, CD8α hinge region, CD28 span Membrane and intracellular domains, 4-1BB intracellular domain, and CD3ζ intracellular domain. The fragments were synthesized by Jinweizhi Company. The obtained gene sequence fragment was connected to the universal lentiviral expression vector PTK881 with restriction sites Age I and Afe I to obtain the plasmid PTK-hGP350-hLMP1 capable of simultaneously expressing LMP1 and GP350 dual-target CAR. The connection steps were completed by Jinweizhi Biotechnology Co., Ltd.

[0027] The constructed plasmid also includes the signal peptide sequence before the light chain of the anti-GP350 single-chai...

Embodiment 2

[0033] Example 2 Construction of CAR-T cells

[0034] Lentivirus packaging: Insert a certain number of 293T cells into a petri dish with a diameter of 10 cm, add 10 mL of DMEM complete medium, and culture several dishes in an incubator containing 5% CO2 at 37°C. When the 293T cells cover about 90% of the culture dish, add 100 μl of DMEM low-sugar medium mixed with 16 μg of the three-plasmid packaging system to the tube of DMEM low-sugar medium containing 48 μl of PEI transfection reagent, vortex, and mix thoroughly. Incubate at 37°C for 30min. Drop the mixture obtained above into a 10cm petri dish, and place it in an incubator containing 5% CO2 at 37°C for culture, change the medium after 6-8 hours, remove all the medium in the 10cm petri dish, add new 10ml DMEM to completely Medium. After 3 days, the cell culture supernatant was collected and filtered through a 0.45 μm filter membrane to obtain the virus initial solution. The three-plasmid packaging system in this example ...

Embodiment 3

[0062] Example 3 Detection of transduction efficiency

[0063] After transducing CAR-T cells, the transduction efficiency of PTK-hGP350-hLMP1 CAR-T cells can be detected, as follows:

[0064] Take 1.0×10 6 After transduction, T cells were incubated with Goat anti-Hμman IgG Antibody and FITC conjμgate at room temperature for 30 minutes, washed twice with normal saline, and the FITC fluorescence signal was detected by flow cytometry, and the ratio of FITC-positive cells was measured. Table 2 reflects the transduction conduction efficiency.

[0065] transduction type transduction efficiency PTK-hGP350-hLMP1 CAR-T cells 29.8％ PTK-hGP350CAR-T cells 32.5％ PTK-hLMP1 CAR-T cells 33.1％

[0066] Table 2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a dual-target chimeric antigen receptor targeting LMP1 and GP350 at the same time, which comprises: the light chain of the anti-GP350 single-chain antibody, the heavy chain of the anti-GP350 single-chain antibody, and the anti-LMP1 single-chain antibody The light chain of anti-LMP1 single chain antibody heavy chain, CD8α hinge region, CD28 transmembrane region and intracellular region, 4‑1BB intracellular region and CD3ζ intracellular region. The dual-target chimeric antigen receptor of the present invention has higher specificity and safety, and has specific killing effect on malignant tumors caused by EBV infection and EBV in the latent stage.

Description

technical field [0001] The invention relates to the technical field of tumor immunotherapy, and provides a method and composition for treating human tumors. The present invention obtains a dual-target chimeric antigen receptor coding gene targeting both LMP1 and GP350 through genetic engineering technology, inserts the fusion gene into an expression vector, and transduces it into human T lymphocytes so that the T cells express the fusion gene. The present invention also relates to a polypeptide expressed by the aforementioned fusion gene, a carrier, and an immune cell expressing the CAR on its surface for immunotherapy. Background technique [0002] Epstein-Barr virus (EBV) is the first tumorigenic virus discovered by humans, its infection rate in the population is as high as 90%, and it is closely related to the occurrence and development of various lymphoid tumors (Plummer M, de Martel C,Vignat J,et al.Global burden of cancers attributable to infections in 2012:asynthetic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/867C12N5/10A61K35/17A61P35/00A61P35/02
CPCC07K16/085C07K14/7051C12N15/86C12N5/0636A61K35/17A61P35/00A61P35/02C07K2319/03C07K2319/33C07K2319/02C07K2317/622C12N2510/00C12N2740/15043
Inventor 桑威
Owner THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap